Impact of imiglucerase on the serum glycosylated-ferritin level in Gaucher disease

被引:17
作者
Stirnemann, Jerome [1 ,2 ]
Boutten, Anne [3 ]
Vincent, Corine [2 ]
Mekinian, Arsene [1 ]
Heraoui, Djazia [4 ]
Fantin, Bruno [4 ]
Fain, Olivier [1 ]
Mentre, France [2 ]
Belmatoug, Nadia [4 ]
机构
[1] Univ Paris 13, Hop Jean Verdier, Assistance Publ Hop Paris, RCLD, F-93140 Bondy, France
[2] Univ Paris Diderot, Hop Bichat, Assistance Publ Hop Paris, Lab Biostat,INSERM UMR 738, F-75018 Paris, France
[3] Hop Bichat Claude Bernard, Assistance Publ Hop Paris, Biochim Lab A, F-75018 Paris, France
[4] Univ Paris 07, Hop Beaujon, Assistance Publ Hop Paris, RCLD, F-92110 Clichy, France
关键词
Gaucher disease; Ferritin; Glycosylated ferritin; Biomarker; ADULT STILLS-DISEASE; IRON OVERLOAD; DIAGNOSIS; HYPERFERRITINEMIA; ELEVATION; MUTATIONS; SECRETION; SUBUNITS; PROTEIN; ENZYME;
D O I
10.1016/j.bcmd.2010.10.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Gaucher disease (GD) is a lysosomal storage disorder, caused by deficient activity of the enzyme glucocerebrosidase, which can be treated by enzyme-replacement therapy (ERT). No prognostic marker can predict long-term complications of GD but several markers are used in therapeutic monitoring: chitotriosidase, total serum ferritin (TSF), angiotensin-converting enzyme (ACE) and tartrate-resistant acid phosphatase (TRAP). They all increase with disease progression and generally decrease under ERT. This study was undertaken to investigate ferritin glycoforms, i.e., glycosylated ferritin (GF) and non-glycosylated ferritin (NGF) concentrations, as potential markers for the follow-up of GD therapy. GF and NGF determinations for GD patients followed in a single center between 1996 and 2007 were analyzed using two approaches: (1) the serum levels of 12 untreated patients were compared with those of 10 patients after 48 months on ERT; (2) the evolution of serum levels under ERT in 15 patients were analyzed using linear/logarithmic mixed models. TSF and NGF levels did not differed significantly between untreated patients and those on ERT (TSF: 524.5 (range 221.0-2045.0) mu g/L vs. 410.5 (range 115.0-1587.0) mu g/L, respectively, p=0.72; NGF: 340.0 (range 182.8-1717.8) mu g/L vs. 199.9 (range 77.1-649.8) mu g/L, p=0.09). The percent GF was significantly lower in untreated patients than in those on ERT (27.0% (range 8.0-51.0) vs. 43.5% (range 22.0-80.0) respectively; p=0.02). The percent GF increased significantly during ERT (slope = 0.156% [95% confidence interval (CI), 0.03; 0.29] per month, p=0.01) regardless of whether NGF and TSF significantly decreased during ERT (slope = -1.4% per month [95%Cl, - 1.9%; - 1.0%], p<0.0001; slope = -1.1% [95%Cl, -1.6%; -0.6%] per month, p<0.0007, respectively). Thus, GF is low in untreated GD patients. GF and NGF changed significantly under ERT and might be of clinical value for GD management under treatment. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:34 / 38
页数:5
相关论文
共 32 条
[1]   Plasma and metabolic abnormalities in Gaucher's disease [J].
Aerts, JMFG ;
Hollak, CEM .
BAILLIERES CLINICAL HAEMATOLOGY, 1997, 10 (04) :691-709
[2]  
Barak V, 1999, EUR CYTOKINE NETW, V10, P205
[3]   GAUCHER DISEASE - NEW MOLECULAR APPROACHES TO DIAGNOSIS AND TREATMENT [J].
BEUTLER, E .
SCIENCE, 1992, 256 (5058) :794-799
[4]   GAUCHER DISEASE [J].
BEUTLER, E .
BLOOD REVIEWS, 1988, 2 (01) :59-70
[5]  
Cabera-Salazar MA, 2004, CLIN CHIM ACTA, V344, P101, DOI 10.1016/j.cccn.2004.02.018
[6]   Hereditary hyperferritinemia-cataract syndrome: Relationship between phenotypes and specific mutations in the iron-responsive element of ferritin light-chain mRNA [J].
Cazzola, M ;
Bergamaschi, G ;
Tonon, L ;
Arbustini, E ;
Grasso, M ;
Vercesi, E ;
Barosi, G ;
Bianchi, PE ;
Cairo, G ;
Arosio, P .
BLOOD, 1997, 90 (02) :814-821
[7]  
DANIELS LB, 1982, CLIN CHEM, V28, P569
[8]   Clinical evaluation of chemokine and enzymatic biomarkers of Gaucher disease [J].
Deegan, PB ;
Moran, MT ;
McFarlane, I ;
Schofield, JP ;
Boot, RG ;
Aerts, JMFG ;
Cox, TM .
BLOOD CELLS MOLECULES AND DISEASES, 2005, 35 (02) :259-267
[9]   Low glycosylated ferritin, a good marker for the diagnosis of hemophagocytic syndrome [J].
Fardet, Laurence ;
Coppo, Paul ;
Kettaneh, Adrien ;
Dehoux, Monique ;
Cabane, Jean ;
Lambotte, Olivier .
ARTHRITIS AND RHEUMATISM, 2008, 58 (05) :1521-1527
[10]  
Fautrel B, 2001, J RHEUMATOL, V28, P322